|Articles|April 1, 1998

Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach
Volume 4
Issue 4 Suppl

Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?

Author(s)William P. Castelli, MD, W. Virgil Brown, MD, Evan A. Stein, MD, PhD

Download PDF: Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?

Articles in this issue

about 28 years ago

Article

Participating Faculty

about 28 years ago

Article

Introduction: Clinical and Economic Considerations of Coronary Heart Disease: A Managed Care Approach

about 28 years ago

Article

Coronary Heart Disease in the United States

about 28 years ago

Article

Mechanisms of Acute Coronary Events

about 28 years ago

Article

Primary Prevention

about 28 years ago

Article

Pravastatin Event Reduction Analysis

about 28 years ago

Article

Secondary Prevention

about 28 years ago

Article

Methods and Mindsets in Pharmacoeconomics

about 28 years ago

Article

Issues and Controversies in Pharmacoeconomics

about 28 years ago

Article

Pharmacoeconomics Perspectives: Payers, Providers, and Patients

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

ByRazanne Oueini, PharmD,Ben Shirley, BS,Christie Teigland, PhD,Melissa Castora-Binkley, PhD, MA,Scott Bilder, PhD,Kiran Sunkari, MS,Lynn Pezzullo, RPh

June 8th 2026

US map with stethoscope | Image Credit: © Andreas Prott - stock.adobe.com

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

ByShifeng Wu, MM

June 5th 2026

Health Care Utilization in Veterans With Alzheimer Disease

ByYing Wang, PhD,Byron J. Aguilar, PhD,Mingfei Li, PhD,Peter Morin, MD, PhD,Joel Reisman, BS,Wen Hu, MS,Jong Soo Lee, PhD,Dan Berlowitz, MD, MPH,Qinqing Li, MS,Raymond Zhang, PhD,Amir Abbas Tahami Monfared, MD, PhD,Quanwu Zhang, PhD,Weiming Xia, PhD

June 4th 2026

Health care costs | Image Credit: © Valeri Luzina - stock.adobe.com

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

ByPooja Chandrashekar, MD, MBA,Sachin H. Jain, MD, MBA

June 4th 2026

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

ByAllison Spitery, PharmD, BCACP,Alison Lobkovich, PharmD, BCACP,Emily Thomas, PharmD, BCPS, BCACP

Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?

Articles in this issue

Related Content

Changes in Persistence to Basal Insulin Following the Medicare Out-of-Pocket Cost Cap

Associations Between Socioeconomic Status, Healthy Lifestyle, and Multimorbidity in the US

Health Care Utilization in Veterans With Alzheimer Disease

What Do We Do With These Prices? Ushering in the Next Phase of Price Transparency Innovation in Medicare Advantage

Real-World Weight Loss With Injectable Semaglutide vs Dulaglutide for Diabetes

Trending on AJMC

Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

GLP-1 Drugs Tackle Both Skin Inflammation and Metabolism in Psoriasis

Childhood Influenza Vaccine Rates Decreased From 2017 to 2023

Oral Orforglipron Added to Basal Insulin Cuts HbA1c in Type 2 Diabetes

Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year